Notice Pursuant to the National Cooperative Research and Production Act of 1993-The Customer Experience Hub

Notice is hereby given that, on January 7, 2026, pursuant to section 6(a) of the National Cooperative Research and Production Act of 1993, 15 U.S.C. 4301 et seq. (“the Act”), The Customer Experience Hub (“CX Hub”) has filed written notifications simultaneously with the Attorney General and the Federal Trade Commission disclosing changes in its membership. The notifications were filed for the purpose of extending the Act's provisions limiting the recovery of antitrust plaintiffs to actual damages under specified circumstances. Specifically, Advanced Biomimetic Sensors, Inc., Bethesda, MD; Advanced RNA Vaccine Technologies, Inc., North Bethesda, MD; Albert Einstein College of Medicine, Bronx, NY; Auspex Medix LLC, Williamsville, NY; Beacon Biosignals, Inc., Boston, MA; Beth Israel Deaconess Hospital—Needham, Inc., Needham, MA; Bethany R. Russell, Ph.D. P.A, Babcock Ranch, FL; Binary Pharmaceuticals LLC, Hot Springs, AR; Bridgesource Medical, Corp., Austin, TX; Broad Clinical Laboratories LLC, Cambridge, MA; Credence Management Solutions Limited Liability Company, Mclean, VA; Delix Therapeutics, Inc., Palo Alto, CA; Droneup LLC, Virginia Beach, VA; Earlham Institute, Norwich, UNITED KINGDOM OF GREAT BRITAIN AND NORTHERN IRELAND; Enveda Therapeutics, Inc., Boulder, CO; Epitel, Inc., Salt Lake City, UT; Georgia Tech Applied Research Corp., Atlanta, GA; Healthspan Action Coalition, Wellington, FL; Hi LLC, Culver City, CA; Huru Ltd, London, UNITED KINGDOM OF GREAT BRITAIN AND NORTHERN IRELAND; Inner Cosmos, Inc., Scotts Valley, CA; Invi Mindhealth, Inc., Parker, CO; IsoLinQ, Sugar Land, TX; Ist, LLC, Birmingham, AL; KBO Systems, Inc., Aurora, CO; Kintsugi Mindful Wellness, Inc., Berkeley, CA; Monash University Clinical Psychedelic Lab, Notting Hill, COMMONWEALTH OF AUSTRALIA; Motif Neurotech, Inc., Houston, TX; Neuro Animation, Inc., Columbia Fls, MT; Neuroblox, Inc., Cambridge, MA; NeuroSigma, Inc., Los Angeles, CA; North Carolina State University Foundation, Inc., Raleigh, NC; Novelna, Inc., Santa Clara, CA; NRx Pharmaceuticals, Wilmington, DE; Osmind, Inc., San Francisco, CA; Oui Therapeutics, Inc., New Haven, CT; Pax Neuroscience, Inc., Glenview, IL; PointHealth AI, San Francisco, CA; Psylo, Inc., Boulder, CO; Relevant LLC; Issaquah, WA; Sage Research Consulting LLC, Mason, OH; Salura Health LLC, McLean, VA; Scottsdale Research Institute, Phoenix, AZ; Senseye, Inc., Austin, TX; Soar Technology LLC, Ann Arbor, MI; Sunstone Therapies, Inc., Rockville, MD; Tactical Mind Research Coalition, St. Petersburg, FL; The Methuselah Foundation, Springfield, VA; The Regents of the University of Colorado, Boulder, CO; The Stories and Wisdom Company, Issaquah; WA; The Virtual Reality Medical Center, a Professional Medical Corporation, San Diego, CA; Toxpath Solutions LLC, Vancouver, WA; University of Arizona, Tucson, AZ; University of California Santa Cruz, Santa Cruz, CA; University of California, Davis, Davis, CA; University of Florida, Gainesville, FL; University of North Carolina at Chapel Hill, Chapel Hill, NC; USAPI Pharma PBC, St. Augustine, FL; Vaccinity, Dallas, TX; and Yale Stress Center, New Haven, CT have been added as parties to this venture.

No other changes have been made in either the membership or planned activity of the group research project. Membership in this group research project remains open, and CX Hub intends to file additional written notifications disclosing all changes in membership.

On January 11, 2024, CX Hub filed its original notification pursuant to section 6(a) of the Act. The Department of Justice published a notice in the Federal Register pursuant to section 6(b) of the Act on April 16, 2024 (89 FR 26929).

The last notification was filed with the Department on October 2, 2025. A notice was published in the Federal Register pursuant to section 6(b) of the Act on February 23, 2026 (91 FR 8525).